We are now accepting applications for the Spring 2026 Scientific Challenge. We invite researchers in academia (PhD students, postdocs, professors) and non-profit organizations to compete for this amazing opportunity.
Accessing advanced tools is often the defining factor in scientific success. This challenge is designed to provide you with the professional tools needed to achieve breakthroughs in computational drug discovery. Whether you are navigating ultra-large Chemical Spaces, performing high-throughput virtual screening, or refining hits with Structure-Based Drug Design (SBDD), our software suite provides the power and speed your project deserves.
The Challenge: Accelerate Your Research
We award our full software portfolio to proposals that demonstrate scientific novelty and a clear vision. By getting this drug discovery software grant, you eliminate the barrier of expensive licensing costs. You gain the ability to aid your hypotheses using our algorithms, ensuring great results for your thesis, dissertation, or peer-reviewed publications.
Awards and Benefits
We select up to 5 winning proposals per quarter based on scientific merit. Winners receive:
- Unrestricted Access: A full 12-month license to BioSolveIT’s complete platform (including SeeSAR for docking/design and infiniSee for Chemical Space navigation).
- Financial Support: The most outstanding project among the winners receives a €1,000 research grant
- Career Visibility: Successful projects are highlighted in our Hall of Fame, offering significant exposure for your work within the scientific community.
Scope of Interest
To win this drug discovery software grant, your proposal should focus on innovative applications of computational chemistry. We are looking for projects involving:
- Structure-Based and Ligand-Based Design
- Fragment-Based Lead Discovery (FBDD)
- Scaffold Hopping and Bioisostere Replacement
- Chemical Space Navigation (billions of compounds)
Elevate your research with the right tools. Submit your proposal by February 21st. For full participation details and eligibility, please review the terms of challenge.